Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System

Rhea-AI Summary

Accuray (NASDAQ: ARAY) announced the first patient treatments with the CyberKnife® System in Austria at the CyberKnife® Center Salzburg. The center utilized Accuray's CyberComm™ technology to commission their latest-generation CyberKnife S7™ System, reducing commissioning time by approximately 50%. The system delivers ultra-hypofractionated radiation therapy in just 1-5 outpatient sessions, compared to conventional 30-40 sessions, with sub-millimeter accuracy.

This installation is particularly significant as Austria's radiotherapy equipment supply is 27% lower than the EU average and 34% lower than economic peers, while cancer cases are projected to increase by 25% between 2022 and 2040. The CyberKnife System's introduction aims to address this healthcare gap and provide more efficient cancer treatment options for Austrian patients.

Positive

• Reduced commissioning time by 50% with CyberComm™ technology
• Treatment completed in 1-5 sessions vs conventional 30-40 sessions
• Expansion into new market (Austria) addressing equipment shortage
• Sub-millimeter accuracy in radiation delivery

Negative

• None.

Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner

MADISON, Wis., May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the CyberKnife^® Center Salzburg is the first in Austria to treat patients with the CyberKnife^® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy. The CyberKnife Center Salzburg's team used the Accuray CyberComm™ technology to commission their system, the latest-generation CyberKnife S7^™ System, making it possible for them to more quickly begin treating patients.

The CyberKnife System facilitates ultra-hypofractionated radiation therapy – very high doses of precisely targeted radiation are delivered in a few days versus conventional fractionation where treatments often require 30-40 sessions. The entire procedure is typically completed in just one to five out-patient sessions, providing access to radiation therapy delivered with sub-millimeter accuracy for people who are unable to travel a month or more for care.

"Growing evidence demonstrates that for some indications, ultra-hypofractionation is a proven treatment modality that delivers clinical outcomes as good as conventional fractionation while dramatically reducing the number of treatments and lowering the total cost of care. This data is driving increased adoption of hypofractionated – and ultra-hypofractionated treatments as the standard of care. With this shift we're seeing more clinicians choose the CyberKnife^® System, which gives them the confidence they need to deliver efficient, yet effective, treatments to their patients," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray.

"Radiation therapy represents an essential treatment option at each stage of the cancer journey, that's why we're committed to providing our customers with the resources they need to get the best possible outcomes with our products," said Suzanne Winter, president and CEO of Accuray. "We look forward to working with the CyberKnife^® Center Salzburg team as they pave the way for improving cancer care. The CyberKnife S7 System is an extremely versatile and precise radiation delivery system, supporting treatment of an expanded range of indications and giving more patients the chance to experience moments that matter."

Estimates suggest the number of cancer cases in Austria will increase by almost 25 percent between 2022 and 2040¹. A European Cancer Inequalities Registry report indicates Austria gets high marks for reimbursement of oncology medications, though the country's supply of radiotherapy equipment is 27 percent lower than the European Union average and 34 percent lower than economic peers². While there has been a positive trend since 2012 to address this, continued installation of devices like the CyberKnife System will be key to closing the gap.

"After many years of treating patients as a radiation oncologist in Germany, it was my mission to bring the CyberKnife System to my home country of Austria. From my perspective if the patient has an appropriate indication for high-dose radiotherapy, the system is the device of choice," said Dr. med. univ. Alfred Haidenberger, CyberKnife^® Center Salzburg. "The CyberKnife System represents a significant advancement in cancer care and will enable patients to undergo highly precise and effective treatment typically in just a few days, avoiding the weeks of daily sessions often required with conventional radiotherapy. These factors have a major impact on the patient's quality of life."

Click here to hear from Dr. med. univ. Alfred Haidenberger about the CyberKnife^® System.

*When compared to traditional CyberKnife^® System commissioning process.

Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations regarding radiation therapy and ultra-hypofractionation, expectations regarding the company's products, clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace; and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 6, 2024, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com

¹ European Cancer Information System (ECIS) of the Joint Research Centre. European Cancer Inequalities Registry. Country Cancer Profile. Accessed March 4, 2025. https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/02/eu-country-cancer-profile-austria-2025_8dd11c12/c8d574cc-en.pdf
² Ibid.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-first-srssbrt-patient-treatments-in-austria-with-the-cyberknife-system-302445766.html

SOURCE Accuray Incorporated

FAQ

What is the significance of ARAY's CyberKnife System launch in Austria?

It's the first CyberKnife System in Austria, addressing the country's 27% lower radiotherapy equipment supply compared to EU average, while cancer cases are expected to rise 25% by 2040.

How does the CyberKnife System's treatment time compare to conventional radiation therapy?

The CyberKnife System completes treatment in 1-5 outpatient sessions, compared to conventional radiation therapy which typically requires 30-40 sessions.

What improvement does Accuray's CyberComm technology offer for the CyberKnife System?

CyberComm technology reduces the system's commissioning time by approximately 50%, allowing facilities to begin patient treatments sooner.

What are the key features of ARAY's CyberKnife S7 System?

The CyberKnife S7 System delivers ultra-hypofractionated radiation therapy with sub-millimeter accuracy, supporting an expanded range of indications with precise radiation delivery.